Patients like DosePro needle free injections – at least compared to their previous triptan treatment.
Earlier this month, Zogenix, Inc. announced the results of their phase 4 clinical study, which was an open label study to see if triptan patients were happy with the switch to SUMAVEL DosePro, a needle free injection system for sumatriptan we’ve talked about before. The results say that patients who currently use triptans in the treatment of multiple migraine attacks reported a higher level of satisfaction, confidence and preference for SUMAVEL DosePro.
The results will be published in the September issue of the journal Headache, The Journal of Head and Face Pain.
The leading author of the study was Dr. Roger K. Cady, associate executive chairman of the National Headache Foundation board of directors. Dr. Cady says about DosePro:
"The Phase 4 study results support the use of SUMAVEL DosePro as an important treatment option for migraine patients, such as those with aggressive, rapid-onset attacks. It provides a fast-acting and easy-to-use injectable triptan therapy option for patients to use as part of their migraine toolbox in conjunction with their oral triptan medications so that the right medication can be used for specific attacks."